Article
The tyrosine kinase inhibitor dasatinib reduces lung inflammation and remodelling in experimental allergic asthma
Registro en:
SILVA, A. L. et al. The tyrosine kinase inhibitor dasatinib reduces lung inflammation and remodelling in experimental allergic asthma. British Journal of Pharmacology, , v.173, p.1236-1247, 2016.
0007-1188
10.1111/bph.13430
1476-5381
Autor
Silva, A. L. da
Magalhães, R. F.
Branco, V. C.
Silva, J. D.
Cruz, F. F.
Marques, P. S.
Ferreira, T. P. T.
Morales, M. M.
Martins, M. A.
Olsen, P. C.
Rocco, P. R. M.
Resumen
Asthma is characterized by chronic lung inflammation and airway hyperresponsiveness. Despite recent advances in understanding of its pathophysiology, asthma remains a major public health problem, and new therapeutic strategies are urgently needed. In this context, we sought to ascertain whether treatment with the TK inhibitor dasatinib might repair inflammatory and remodelling processes, thus improving lung function, in a murine model of asthma. 2030-01-01